Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Glaukos reported a quarterly loss of $0.40 per share, better than the Zacks Consensus Estimate of a loss of $0.43, and an improvement from a loss of $0.63 per share a year ago, representing an earnings surprise of 6.98% [1] - The company posted revenues of $105.5 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.71%, and showing an increase from year-ago revenues of $82.37 million [2] - Over the last four quarters, Glaukos has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Outlook - Glaukos shares have increased approximately 7.1% since the beginning of the year, outperforming the S&P 500's gain of 4.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.35 on revenues of $106.44 million, and -$1.08 on revenues of $477.69 million for the current fiscal year [7] - The estimate revisions trend for Glaukos is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Glaukos belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]